ArticleIJU case reports2025
Muscle invasive bladder cancer treated with gemcitabine plus cisplatin as neoadjuvant chemotherapy during the second trimester of pregnancy.
Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Muscle invasive bladder cancer during pregnancy is scarcely reported. Case presentation: A 41-year-old ex-smoker Asian female, managed with clean intermittent catheterization for 3 years due to neurogenic bladder caused by spinal cord disease, presented with gross hematuria at 10 weeks of gestation. The patient was diagnosed with muscle invasive bladder cancer, cT3aN0M0. Maternal treatment was prioritized and gemcitabine plus cisplatin as neoadjuvant chemotherapy was started at 17 weeks of gestation. Cesarean section was performed at 32 weeks of gestation, followed by robot-assisted radical cystectomy 3 weeks later. Histopathological examination revealed urothelial carcinoma, G3, ypT3b. Postoperative adjuvant nivolumab followed by enfortumab vedotin was not successful and the patient died 8 months after robot-assisted radical cystectomy. Unfortunately, the premature infant with congenital heart disease died of necrotizing enterocolitis at 1-month-old. Conclusion: Gemcitabine plus cisplatin chemotherapy in the patient with muscle invasive bladder cancer during pregnancy was safe but ultimately resulted in unfavorable outcomes in this case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.